Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodríguez‐Otero, Sergio Giralt, Sikander Ailawadhi et al.|New England Journal of Medicine|2023Cited by 695
Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a <scp>SEER</scp>‐medicare analysisSikander Ailawadhi, Asher Chanan‐Khan, Ryan D. Frank et al.|Cancer Medicine|2017Cited by 88
Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparitiesSikander Ailawadhi, Asher Chanan‐Khan, Ryan D. Frank et al.|Cancer|2018Cited by 55
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label TrialSikander Ailawadhi, Yifan Zhai, Zi Chen et al.|Clinical Cancer Research|2023Cited by 38
Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centersYanyan Lou, Sikander Ailawadhi|Cancer Medicine|2018Cited by 34